What’s in the Pipeline: New HIV Drugs, Vaccines, Microbicides, HCV and TB Therapies in Clinical Trials By Rob Camp, Richard Jefferys, Tracy Swan & Javid Syed Edited by Bob Huff August 2006 From the Forword: Twenty-five years into the global…
By Rob Camp May 25, 2006 Darunavir (DRV) is a ritonavir(r)-boosted protease inhibitor that has been studied for use in heavily treatment-experienced patients. In the future, DRV/r will be evaluated for use in less-experienced, treatment-naïve and pediatric populations. The current…
Published 2006 This publication is cosponsored by the Open Society Institute, a private operating and grantmaking foundation whose aim is to shape public policy in order to promote democratic governance, human rights, and economic, legal, and social reform, and the…
by Mark Harrington Remarks at Boehringer Ingelheim Symposium “HIV: From Yesterday to Tomorrow / HIV: da ieri in poi” Sheraton Golf Parco de’Medici 6 April 2006 Rome * [Note: This is a revised and expanded version of remarks I gave…
What’s in the Pipeline: New HIV Drugs, Vaccines, Microbicides, HCV and TB Treatments in Clinical Trials By Rob Camp, Richard Jefferys, Tracy Swan & Javid Syed Edited by Mark Harrington & Bob Huff July 2005 From the Introduction: This overview…
TREATMENT ACTION GROUP SUPPORTS ACCELERATED F.D.A. APPROVAL FOR NOVEL PROTEASE INHIBITOR TIPRANAVIR NEW YORK, NY, 19 May 2005 Rob Camp, Antiretoviral Project Director for the Treatment Action Group (TAG), today testified in favor of Food and Drug Administration (FDA) accelerated…
By Bob Huff December 2004 Introduction The 3rd International Community TB/HIV Workshop was held in Paris from October 26-29, 2004. Participants were nominated by organizations and networks from all regions. From 229 applicants the Advisory Committee — Beverley Figaji (Namibia),…